$NBEV was hoping to get back in the 1.80 levels, but the FDA announcement that CBD is not recognized as safe is huge. They won’t be changing that decision any time soon. Since that was meant to be the only catalyst for this stock, this stock will continue to dive. The core biz is not growing and cash flow will continue to bleed.
  • 2
  • 10